News >

Cetuximab Plus Pembrolizumab Well Tolerated in RAS Wild-Type mCRC

Angelica Welch
Published: Saturday, Jan 20, 2018

Patrick Boland, MD

Patrick Boland, MD
The combination of cetuximab (Erbitux) and pembrolizumab (Keytruda) was found to be well tolerated in patients with RAS wild-type metastatic colorectal cancer (mCRC), according to findings of a phase Ib/II study presented at the 2018 Gastrointestinal Cancers Symposium.

wild-type and have received at least 1 prior systemic therapy in the metastatic or unresectable disease setting, are naïve to anti-EGFR therapy, and have measurable disease per RECIST 1.1 criteria.
Boland PM, Hutson A, Maguire O, et al. A phase Ib/II study of cetuximab and pembrolizumab in RAS-wt mCRC. J Clin Oncol. 2018;36(suppl 4S; abstr 834).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication